The company was founded in 1956, issued A-shares and listed in 2000. It is a state-owned listed company. After more than 60 years of development, Haizheng Pharmaceutical has become a comprehensive pharmaceutical enterprise group integrating the entire value chain of research, production and marketing, and vertical integration of APIs and pharmaceuticals. The company is a comprehensive pharmaceutical enterprise integrating the entire value chain of research, production and marketing, integration of APIs and formulations, and multi-regional development. It focuses on the development of various industries such as chemicals, biopharmaceuticals, animal medicine, traditional Chinese medicine and pharmaceutical commerce, and is accelerating the deployment of large health industries and emerging markets such as health aesthetics. The company's main products include: doractin, injectable methylprednisolone succinate, injectable piperacillin sodium, tazobactam sodium, amlodipine atorvastatin calcium tablets, etc. Corporate honors: Received honors such as “National High-tech Enterprise” and “National May Day Labor Award”, and was selected as the country's first batch of “Innovative Enterprises” and “National Intellectual Property Demonstration Enterprises”.
No Data